|
|
(3 intermediate revisions by the same user not shown) |
Line 42: |
Line 42: |
| | | |
| </article> | | </article> |
− |
| |
| <article class="col-xs-12 col-sm-12 col-md-10 col-md-offset-1" id="Strategies"> | | <article class="col-xs-12 col-sm-12 col-md-10 col-md-offset-1" id="Strategies"> |
| <h1>Strategies</h1> | | <h1>Strategies</h1> |
− | <div class="row"> | + | <div class="row" style="text-align:center;"> |
− | <div class="col-md-6">
| + | |
| <h2>BEVS</h2> | | <h2>BEVS</h2> |
| <img src="https://static.igem.org/mediawiki/2015/7/7d/Tec-Monterrey_Baculovirus_1.jpg" class="img-responsive"> | | <img src="https://static.igem.org/mediawiki/2015/7/7d/Tec-Monterrey_Baculovirus_1.jpg" class="img-responsive"> |
− | </div>
| |
− | <div class="col-md-6">
| |
| <p align="justify">Characterization of the widely used polyhedrin promoter (<a href="http://parts.igem.org/Part:BBa_K173400">BBa_K1734000</a>) and the confirmation of two secretion signals (<a href="http://parts.igem.org/Part:BBa_K1734001">BBa_K1734001</a>, <a href="http://parts.igem.org/Part:BBa_K1734002">BBa_K1734002</a>). All the work was confirmed by using the reporter gene Nanoluc (<a href="http://parts.igem.org/Part:BBa_K1734004">BBa_K1734004</a>)</p> | | <p align="justify">Characterization of the widely used polyhedrin promoter (<a href="http://parts.igem.org/Part:BBa_K173400">BBa_K1734000</a>) and the confirmation of two secretion signals (<a href="http://parts.igem.org/Part:BBa_K1734001">BBa_K1734001</a>, <a href="http://parts.igem.org/Part:BBa_K1734002">BBa_K1734002</a>). All the work was confirmed by using the reporter gene Nanoluc (<a href="http://parts.igem.org/Part:BBa_K1734004">BBa_K1734004</a>)</p> |
− | </div>
| |
| </div> | | </div> |
− | <div class="row"> | + | <div class="row" style="text-align:center;"> |
− | <div class="col-md-6">
| + | |
| <h2>STABLE</h2> | | <h2>STABLE</h2> |
| <img src="https://static.igem.org/mediawiki/2015/6/61/Tec-Monterrey_Stable_Line_1.jpg" class="img-responsive"> | | <img src="https://static.igem.org/mediawiki/2015/6/61/Tec-Monterrey_Stable_Line_1.jpg" class="img-responsive"> |
− | </div>
| |
− | <div class="col-md-6">
| |
| <p align="justify">Random genome integration to generate a stable cell line mediated by zeocin antibiotic resistance by selective pressure. The promoter OpIE2 (<a href="http://parts.igem.org/Part:BBa_K1734001">BBa_K1734001</a>) was used to test protein production.</p> | | <p align="justify">Random genome integration to generate a stable cell line mediated by zeocin antibiotic resistance by selective pressure. The promoter OpIE2 (<a href="http://parts.igem.org/Part:BBa_K1734001">BBa_K1734001</a>) was used to test protein production.</p> |
− | </div>
| |
| </div> | | </div> |
− | <div class="row"> | + | <div class="row" style="text-align:center;"> |
− | <div class="col-md-6">
| + | <h2>CRISP/Cas9</h2> |
− | <h2>CRISPR/Cas9</h2> | + | <img src="https://static.igem.org/mediawiki/2015/c/c2/Tec-Monterrey_Crispr_1.jpg" class="img-responsive"> |
− | <img src="https://static.igem.org/mediawiki/2015/c/c2/Tec-Monterrey_Crispr_1.jpg" class="img-responsive"> | + | |
− | </div>
| + | |
− | <div class="col-md-6">
| + | |
| <p align="justify">To prove the function of the CRISPR/Cas9 in the Sf9, we developed two constructs of our gRNA (<a href="http://parts.igem.org/Part:BBa_K1734012">BBa_K1734012</a>, <a href="http://parts.igem.org/Part:BBa_K1734013">BBa_K1734013</a>) to attenuate the Nanoluc’s luminescence in the stable cell line. These gRNAs are in the same plasmid that produces the Cas9 protein and a GFP protein as a fluorescent marker, having two separate plasmids. We will work with both pathways of CRISPR: nonhomologous end joining and homology-directed repair.</p> | | <p align="justify">To prove the function of the CRISPR/Cas9 in the Sf9, we developed two constructs of our gRNA (<a href="http://parts.igem.org/Part:BBa_K1734012">BBa_K1734012</a>, <a href="http://parts.igem.org/Part:BBa_K1734013">BBa_K1734013</a>) to attenuate the Nanoluc’s luminescence in the stable cell line. These gRNAs are in the same plasmid that produces the Cas9 protein and a GFP protein as a fluorescent marker, having two separate plasmids. We will work with both pathways of CRISPR: nonhomologous end joining and homology-directed repair.</p> |
− | </div>
| |
| </div> | | </div> |
| </article> | | </article> |
Line 1,471: |
Line 1,458: |
| These results confirm the activity of the pPH promoter at 72 h post-transfection. They also confirm the activity of the secretion peptide HBM that was fused to the reporter protein Nanoluc. | | These results confirm the activity of the pPH promoter at 72 h post-transfection. They also confirm the activity of the secretion peptide HBM that was fused to the reporter protein Nanoluc. |
| The observed data indicates the predominant presence of Nanoluc in the supernatant due to the secretion signal. Also we found luminescence in the interior of the cells but the signal was 86 times lower. We estimate a percentage of secretion efficiency of 98.85%</p> | | The observed data indicates the predominant presence of Nanoluc in the supernatant due to the secretion signal. Also we found luminescence in the interior of the cells but the signal was 86 times lower. We estimate a percentage of secretion efficiency of 98.85%</p> |
− | <table> | + | <div class="row" style="text-align: center"> |
| + | <br/> |
| + | <table class="table"> |
| <tr> | | <tr> |
| <th>Experiment</th> | | <th>Experiment</th> |
Line 1,492: |
Line 1,481: |
| </table> | | </table> |
| <strong>Table 2. Efficiency of secretion signal HBM.</strong> | | <strong>Table 2. Efficiency of secretion signal HBM.</strong> |
| + | </div> |
| + | <br/> |
| <p> | | <p> |
| Since the fluorescence of RFP wasn’t detected, we assume that the T2A is not working in its cleavage mechanism which means that the RFP probably continued to be fused with Nanoluc by the T2A. We conclude that the T2A doesn’t work in Sf9 cells but we’ll do more experiments to confirm the size of the complex/fused protein. We’d also continue to study this mechanism because the hydrolysis of the peptidyl:glycyl-tRNA ester linkage was not completely understood.</p> | | Since the fluorescence of RFP wasn’t detected, we assume that the T2A is not working in its cleavage mechanism which means that the RFP probably continued to be fused with Nanoluc by the T2A. We conclude that the T2A doesn’t work in Sf9 cells but we’ll do more experiments to confirm the size of the complex/fused protein. We’d also continue to study this mechanism because the hydrolysis of the peptidyl:glycyl-tRNA ester linkage was not completely understood.</p> |